Companies with CEO Buys of Over 50k Shares in April 2011

ParkerVision PRKR ParkerVision, Inc. designs, develops and markets its proprietary RF technologies which enable advanced wireless communications for current and next generation mobile communications networks. Its solutions for wireless transfer of radio frequency (RF) waveforms enable significant advancements in wireless products, addressing the needs of the cellular industry for efficient use of power, reduced cost and size, greater design simplicity and enhanced performance in mobile handsets as the industry migrates to next generation networks. Parkervision closed out the sale of 3.3 million shares in March 2011. The stock is up nearly 50% YTD. Excel Trust EXL Excel Trust, Inc. is a retail focused REIT that targets community and power centers, grocery anchored neighborhood centers and freestanding retail properties. Earlier this month, Excel purchased two properties for a total of $92.1 million in cash and shares. Equities research analysts at UBS AG UBS downgraded shares of Excel from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday. AVI Biopharma AVII AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. The United States Adopted Names Council has approved the nonproprietary name eteplirsen for AVI-4658, the Company's exon-skipping therapy for the treatment of Duchenne muscular dystrophy, a genetic muscle wasting disease caused by the absence of functional dystrophin. In addition, the World Health Organization has approved eteplirsen as the International Nonproprietary Name for AVI-4658. Rexahn Pharmaceuticals RNN Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. In March, the company announced the closing of a previously announced sale of an aggregate of $10 million of securities in a registered direct offering.